AKT1 and cancer: Since, dysregulation of PI3Ks and their downstream effector molecules forming the PI3K/Akt/mTOR axis contribute to cancer initiation, progression, and growth, HDACIs are used as single drugs to test whether their anticancer effect involves inhibition of PI3Ks in different cancer cells and in animal xenograft cancer models.